Signifor approved for Cushing's disease

December 17, 2012

(HealthDay)—Signifor (pasireotide diaspartate) has been approved by the U.S. Food and Drug Administration to treat Cushing's disease in cases that cannot be treated by surgery.

Cushing's occurs when the body overproduces cortisol, a hormone made by the . Cortisol helps regulate the body's reaction to stress and injury. People with Cushing's may be overweight, glucose intolerant, diabetic, have high blood pressure, bruise easily and be at increased risk of infection, the agency said in a news release.

Signifor was evaluated in a clinical study of 162 people with Cushing's disease, and a reduction in cortisol production was seen in as little as one month. About 20 percent of people had cortisol levels within the normal range by the end of the six-month study, the FDA said.

The most common adverse reactions to the twice-daily injected drug included , diarrhea, nausea, abdominal pain and gallstones.

The agency said it is requiring the drug's Swiss maker, Novartis, to conduct three post-approval studies to evaluate Signifor's effects on factors including high blood sugar management, and the potential for acute and adrenal insufficiency.

Explore further: New model taps tiny, common tropical fish for large-scale drug screening to combat Cushing disease

More information: Medline Plus has more about Cushing's disease.

Related Stories

Synribo approved to treat rare leukemia

October 26, 2012

(HealthDay)—Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).

Iclusig approved for rare leukemias

December 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Recommended for you

FDA bolsters warnings about class of antibiotics

July 26, 2016

(HealthDay)—The U.S. Food and Drug Administration announced Tuesday that it's strengthening label warnings on a class of antibiotics called fluoroquinolones because the drugs can lead to disabling side effects, including ...

Why kicking the opioid habit can be so tough

July 20, 2016

(HealthDay)—He was 26, a specialist fifth class with the U.S. Army, and stationed abroad, when an accident on the German autobahn sent him careening through the windshield of his car.

New research shows vaccine protection against Zika virus

June 28, 2016

The rapid development of a safe and effective vaccine to prevent the Zika virus (ZIKV) is a global priority, as infection in pregnant women has been shown to lead to fetal microcephaly and other major birth defects. The World ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.